All News

Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G
Bonnia Liu bonnialiu ( View Tweet)
Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at
Pedro Castillo _Castillo_Pedro ( View Tweet)
More thoughts from @ashira_md's talk on Gaslighting/microaggressions from #ACR21 ... (Q 1/2) Providers: have you ever been told you are difficult and/or challenging?

Elizabeth Graef SituationRheum ( View Tweet)

Abst 1661 Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA - In women: Depression significantly associated w/ disability - In men: HTN & Lung Disease significantly associated w/ disability #ACR21 @RheumNow https://t.co/0qkn1TcvOi
Akhil Sood MD AkhilSoodMD ( View Tweet)
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY

Links:

Janet Pope Janetbirdope ( View Tweet)

#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm

Links:

Janet Pope Janetbirdope ( View Tweet)

Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we break cycle by ⬆️adherence & health literacy, d/c smoking, use drug levels, biomarkers. Oh that in in future #ACR meetings! #ACR21 abst#1830 @RheumNow https://t.co/GyhgUGHWe8

Links:

Janet Pope Janetbirdope ( View Tweet)

Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology​). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
Katie Poholek kpoho ( View Tweet)
Similar effects in those with CKD stage 3, with also high proportion of achieving serum urate target <6mg/dL (overall 99% of study sample achieved target during trial) https://t.co/gKvDJKoWuw
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
OA oral session - abstract 1904 Devin Driscoll (mentor @tuhina_neogi) presenting data from MOST: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement #ACR21 https://t.co/APZAJdHH5M
Rheum Cat rheum_cat ( View Tweet)
Dr Ami Shah - Scleroderma & Cancer: 🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective? 🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below #ACR21 #ACRambassador https://t.co/2VcWn2UInm
Didem Saygin, MD didemsayginmd ( View Tweet)
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Janet Pope Janetbirdope ( View Tweet)
Hair Loss due to Methotrexate from RCTs in RA estimated at 6.9%. It's an understandable source of concern for those taking the medication #ACR21 https://t.co/GymV2RC7jT
Dr Irwin Lim _connectedcare ( View Tweet)
@ashira_md blazing through again! Tune in now to hear her talk on #microaggressions and #gaslighting #ACR21 #ACRAmbassador #DEI https://t.co/uqvLxxcs43
Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)
🆕 Main findings of #Lupus trials presented at #ACR21 ⬇️ https://t.co/HENxcyLuf5
Laurent ARNAUD Lupusreference ( View Tweet)
🗳️Poll of the day for #ACR21 #ACRambassador @ACRheum 🤔What format do you prefer for #ACR22?

Herman Tam DrPedsRheum ( View Tweet)

Dr. Lane on Ca/Vitamin D in Osteoporosis ⭐️🎯serum vitamin D 25OH ~38 ⭐️Studies since 2008 Auckland Calcium trial DO NOT support incr CV risk with Ca supplementation ⭐️Ca calculator: https://t.co/PLPMfZdIwb ⭐️No sig change in fracture risk with supp #ACR21 #ACRAmbassador https://t.co/KUa52vf4gT

Links:

Veena Katikineni VeenaRheumMD ( View Tweet)
×